Boston, MA 03/12/2013 (wallstreetpr) – The Sapien device manufactured by Edwards Lifesciences Corp (NYSE:EW) is as effective and safe as an open heart surgery and has the capacity to last for at least three years say researchers. This device is implanted in the heart to fix a diseased aortic valve and a catheter is used to insert it into place. The American College of Cardiology has presented a study at a San Francisco meeting regarding the device. It had received the go-ahead from U.S regulators in October and the data is very reassuring. It is poised to be the first real alternative to traditional surgery. The trail that had been dubbed “Partner” found that only 44.2 percent of patients who had undergone Sapien implants died in comparison to the 44.8 percent of surgery deaths.
Stroking away the danger
Complications such as strokes are a definite threat when any device is inserted into the heart. The results produced by the study in this context were also very favorable as the stroke-risk evened out over a period of time. Close to 9.3 percent of open-heart surgery patients suffer a stroke after three years. In comparison, the Sapien patients fared better with 8.2 percent suffering strokes. Brigham’s and Women’s hospital’s director of clinical cardiology, Patrick O’Gara said that the devices are a huge leap in the treatment of damaged aortic valves. This in particular for those patients whose chances of not faring too well in an open heart surgery are low. It will take some time for solid proof about their lasting-capacity to come through. The devices that replace the aortic valve in standard surgeries have the capacity to last for decades.
Shares of Edwards Lifesciences Corp (NYSE:EW) went down by 2.47% to close at $88.07
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com